Interestingly, complete tumor regression was observed with anti-CTLA-4 antibody therapy, even in ULBP2-expressing tumors, suggesting that immune suppression induced by ULBP2 can be overcome under certain conditions. This evidence concerns the gene CTLA4 and neoplasm.